Regeneron bets $75M on Infinimmune antibody platform

What's the deal? InfinimmuneDealroom has a profile for this one. Try Dealroom →, an Alameda, California biotech developing antibody therapeutics derived from the human immune system, has raised a $75 million Series A. Regeneron VenturesDealroom has a profile for this one. Try Dealroom → led the round alongside Playground GlobalDealroom has a profile for this one. Try Dealroom →, with participation from RA Capital Management, Goldcrest CapitalDealroom has a profile for this one. Try Dealroom →, Forge Life Science PartnersDealroom has a profile for this one. Try Dealroom → and Merck Global Health Innovation FundDealroom has a profile for this one. Try Dealroom →.

What's the endgame? The financing will fund two lead antibodies for atopic dermatitis, both due to enter Phase 1 trials in 2027. IFX-201 targets interleukin-13, while IFX-101 targets interleukin-22, a pathway with no approved biologic.

Why now? The round follows Infinimmune's March 2026 partnership with MerckDealroom has a profile for this one. Try Dealroom →, valued at up to $838 million, and gives the company capital to advance its preclinical pipeline. The company was co-founded by Wyatt McDonnellDealroom has a profile for this one. Try Dealroom →, its chief executive.

Read more: Fierce Biotech · Business Wire

Image credit: Generated with Gemini